FiguresAfter playing the "pipeline" card for a while and apparently not pulling any punches in the market, the stock market is more likely to focus on the Q4 or 2022 figures and the outlook for 2023 in the coming weeks.
Unfortunately, the Q4 numbers are likely to disappoint the market, with Gilles only expecting sales of $3-3.5 mill.
Ceapro is still living off its outstanding 1st and 2nd quarter numbers. Hopefully the full year 2022 trend will continue in the current year.